The purpose of this study is to assess the efficacy and safety of Amaryl when added to
Metformin and Thiazolidinedione (TZD) in non-insulin dependent diabetes mellitus (NIDDM)
- Patients must have given their signed informed consent.
- Males or females between 18 and 80 years old. Female patients must be surgically
sterile, post-menopausal, or using an accepted method of birth control (i.e., oral
contraceptives, intrauterine device, Norplant® system, Depo Provera®, or a spermicide
and condom). Female patients of childbearing potential must have a negative serum
pregnancy test and be advised not to become pregnant during the study.
- At least 1 year history of NIDDM and performing home blood glucose monitoring.
- Patients must have BMI of > 26 to < 42 kg/m2 at baseline (week 0).
- Patients must have HbA1C > 7.5% but < 9.5% at screen (week -4).
- Patients must have evidence of insulin secretory capacity (fasting C-peptide
concentration > or equal to 0.27 nmol/l during the stabilization period).
- Patients must have FPG > 130 mg/dl but < 235 mg/dl prior to (within 48-72 hours)
randomization at Visit 1 Week 0.
- Patients must be receiving as their current diabetic therapy stable doses of
metformin (at dose of 1.0-2.5gm/day), or metformin extended release at a maximum
dose of 2 gm/day and a half maximum to a maximum dose of thiazolidinedione for at
least 3 months.
- Patients must be able to understand and willing to adhere to and be compliant with
the study protocol.
- Patients who require insulin therapy or are currently on other sulfonylureas.
- Patients with a history of hypersensitivity to sulfonylureas.
- Patients with past history of severe hypoglycemia reaction on their current
antidiabetic therapy requiring medical attention.
- Patients with a history of acute metabolic complications such as hyperosmolar coma or
- Patients with clinically significant abnormal baseline laboratory values (hematology,
blood chemistry or urinalysis) which define a disease or condition, which in the
opinion of the investigator may either put the patient at risk because of
participation in the study, or may influence the results of the study, or the
patient's ability to participate and complete the study. Should there be a laboratory
value which, upon initial screening, is substantially outside the normal range, the
test should be repeated.
- Patients who had an increase in their thiazolidinedione medication within 2 months of
entering the study (Visit 0).
- Patients who had an increase in the metformin medication within 1 month of entering
the study (Visit 0).
- Patients whose body weight has changed more than 2% for patients < 250 pounds or 3%
for patients >= 250 pounds, during the 4 week stabilization period when compared to
the weight at the screening visit 0 (week - 4).
- Patients with acute infections.
- Patients who have received any drug (i.e. a chemotherapy agent) with a well-defined
potential for toxicity to a major organ system during the three months prior to the
- Patients with clinically significant renal or hepatic disease (i.e. ALT > 2.5 x upper
limit of normal) or gastrointestinal disorders that may interfere with absorption of
the study drugs.
- Patients who are allergic to sulfonamides and excipients.
- Patients with any history of alcohol or drug abuse.
- Pregnant or lactating females will be excluded.
- Patients with a history of psychosis, emotional or intellectual problems that could
impair the ability of the patient to participate in the study or to complete the
- Patients who have participated in any investigational study within 30 days prior to